Objective quantification of vitreous inflammation using optical coherence tomography

使用光学相干断层扫描客观量化玻璃体炎症

基本信息

  • 批准号:
    10574348
  • 负责人:
  • 金额:
    $ 25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-01 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Uveitis involving the posterior segment has the highest rate of vision impairment and development of ocular complications among patients with uveitis. Clinical grading of vitreous inflammation utilizes the widely accepted Standardization of Uveitis Nomenclature (SUN) Working Group criteria. However, several limitations exist with the SUN criteria because it is a subjective, semi-quantitative, stepwise grading system. A rapid, reproducible, and quantitative technique to evaluate inflammation is of paramount importance. The NEI-funded First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial was a multicenter, randomized, parallel, observer-masked clinical trial where 216 participants were randomized to receive oral methotrexate 25 mg weekly or oral mycophenolate mofetil 1.5 g twice daily. All participants were at least 16 years of age and had active non-infectious intermediate, posterior, or panuveitis in at least one eye and had justification for starting corticosteroid-sparing immunomodulatory therapy. Participants in this trial were followed up over a period of 12 months. As part of the FAST Trial, all participants underwent optical coherence tomography (OCT) imaging at baseline and at monthly intervals during the 12-month follow-up period. The robust and detailed nature of this randomized clinical trial combined with standardized OCT imaging at every visit will allow us to evaluate objective imaging biomarkers of vitreous inflammation, compare these biomarkers with clinical grading, and correlate these biomarkers with clinical outcomes and development of ocular complications. This proposal is for a secondary analysis of the FAST Trial OCT dataset and we will pursue the following specific aims: 1) develop a standardized, reproducible technique using OCT to quantify vitreous cells, 2) evaluate a reproducible technique using OCT to quantify vitreous haze, and 3) create a predictive risk stratification model based on objective measures of intraocular inflammation. The long-term goal is that these results would support the use of objective measures in routine clinical practice and as endpoints in clinical trials. The aims of this study will address the NEI strategic plan for the area of emphasis relating to the “Immune System and Eye Health”. This study will identify imaging biomarkers of ocular inflammation that will help in disease detection and surveillance. Ultimately, earlier detection and improved monitoring of uveitis can prevent permanent vision loss and disability.
项目摘要 葡萄膜炎累及眼后段,视力损害和眼内损害的发生率最高, 葡萄膜炎患者的并发症。玻璃体炎症的临床分级利用广泛接受的 葡萄膜炎命名(SUN)工作组标准的标准化。然而, SUN标准,因为它是一个主观的,半定量的,逐步分级系统。一种快速,可重复, 而定量技术评价炎症是至关重要的。NEI资助的一线 抗代谢药物作为类固醇保留治疗(FAST)葡萄膜炎试验是一项多中心,随机,平行, 216名受试者随机接受口服甲氨蝶呤25 mg的双盲临床试验 每周或口服吗替麦考酚酯1.5 g,每日两次。所有参与者均年满16岁, 至少一只眼睛患有活动性非感染性中间、后部或全葡萄膜炎,并有理由开始治疗 保留皮质类固醇的免疫调节治疗。这项试验的参与者被随访了12年, 个月作为FAST试验的一部分,所有参与者均接受了光学相干断层扫描(OCT)成像, 基线和12个月随访期间每月一次。这种强大而详细的特性 随机临床试验结合每次访视时的标准化OCT成像将使我们能够评估 玻璃体炎症的客观成像生物标志物,将这些生物标志物与临床分级进行比较, 将这些生物标志物与临床结果和眼部并发症的发展相关联。这项建议是 对FAST试验OCT数据集进行二次分析,我们将追求以下具体目标:1) 开发一种标准化的,可重复的技术,使用OCT来量化玻璃体细胞,2)评估 使用OCT量化玻璃体混浊的可重复技术,以及3)创建预测性风险分层模型 基于眼内炎症的客观测量。长期目标是这些结果将 支持在常规临床实践中使用客观指标,并将其作为临床试验的终点。 这项研究的目的是解决国家教育倡议战略计划的重点领域有关的“免疫 系统和眼睛健康”。这项研究将确定眼部炎症的成像生物标志物,这将有助于 疾病检测和监测。最终,早期发现和改善葡萄膜炎的监测可以预防 永久性视力丧失和残疾。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edmund Tsui其他文献

Edmund Tsui的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edmund Tsui', 18)}}的其他基金

Objective Measures of Intraocular Inflammation in Pediatric Anterior Uveitis
小儿前葡萄膜炎眼内炎症的客观测量
  • 批准号:
    10462742
  • 财政年份:
    2021
  • 资助金额:
    $ 25万
  • 项目类别:
Objective Measures of Intraocular Inflammation in Pediatric Anterior Uveitis
小儿前葡萄膜炎眼内炎症的客观测量
  • 批准号:
    10283026
  • 财政年份:
    2021
  • 资助金额:
    $ 25万
  • 项目类别:
Objective Measures of Intraocular Inflammation in Pediatric Anterior Uveitis
小儿前葡萄膜炎眼内炎症的客观测量
  • 批准号:
    10673102
  • 财政年份:
    2021
  • 资助金额:
    $ 25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了